肺炎支原体致病机制及其疫苗的研究进展  

Pathogenesis of Mycoplasma pneumonia infection and vaccine development

作　　者：王慧霞(综述) 李羚(审校)[1] WANG Hui-xia;LI Ling(Department of Respiratory Medicine,Wuxi Children s Hospital Affiliated to Nanjing Medical University,Wuxi 214000,Jiangsu Province,China)

机构地区：[1]南京医科大学附属无锡儿童医院呼吸科,江苏无锡214000

出　　处：《微生物学免疫学进展》2022年第1期77-82,共6页Progress In Microbiology and Immunology

基　　金：无锡市卫生健康委员会重大项目(Z202016)。

摘　　要：肺炎支原体(Mycoplasma pneumoniae, MP)是导致儿童社区获得性肺炎的常见病原体之一。MP感染人体后可造成多个系统的损害。随着耐药现象的出现,重症或难治性肺炎患儿增多,为临床治疗带来了巨大的挑战。疫苗是预防肺炎支原体肺炎(Mycoplasma pneumoniae pneumonia, MPP)最有效的手段,但人用MP相关疫苗尚在研发之中。现将MP致病机制和疫苗相关研究作一概述。Mycoplasma pneumoniae(MP) is one of the common pathogens that cause community-acquired pneumonia(CAP) in children. People infected with MP present concomitant multiple organ damage of lung, heart, kidney, among others. With the emergence of drug resistance of MP, the number of children with severe or refractory pneumonia has increased, which has brought huge challenges to clinical treatment. Vaccination is the most effective approach in the prevention of Mycoplasma pneumoniae pneumonia(MPP), nevertheless, Mycoplasma pneumonia vaccines for human are still under development. The main pathogenic mechanism of MP infection and vaccine-related research are now summarized.

关 键 词：肺炎支原体 社区获得性肺炎 致病机制 疫苗 

分 类 号：R725.6[医药卫生—儿科]